Showing results (541-550 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|August 29, 2009
Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendationsDyfrig A Hughes, Lesley Tilson, Michael DrummondPharmacoeconomics|August 29, 2009
Determinants of willingness to pay for a new therapy in a sample of menopausal-aged womenAndrej Rasch, Jan-Marc Hodek, Claus Runge, et al.Pharmacoeconomics|August 12, 2009
Costs of illness in a Russian cohort of patients with Parkinson's diseaseYaroslav Winter, Sonja von Campenhausen, Georgy Popov, et al.Pharmacoeconomics|August 12, 2009
Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in JapanTakeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, et al.Pharmacoeconomics|April 10, 2009
Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in BelgiumLieven Annemans, Vanessa Rémy, James Oyee, et al.Pharmacoeconomics|January 31, 2009
Is medication review by primary-care pharmacists for older people cost effective?: a narrative review of the literature, focusing on costs and benefitsArnold G Zermansky, Jonathan SilcockPharmacoeconomics|January 31, 2009
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysisNick Bansback, Roberta Ara, Sue Ward, et al.Pharmacoeconomics|January 31, 2009
Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implicationsShien Guo, Duygu Bozkaya, Alexandra Ward, et al.Pharmacoeconomics|July 16, 2008
Waiting for reimbursement of new medicines in Canada: it's time for a rethinkBrett J SkinnerPharmacoeconomics|September 18, 2009
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plansRonald R White, Greg Lenhart, Puneet K Singhal, et al.Pageof 335